129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

ConditionsPulmonary Arterial Hypertension Idiopathic Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)Connective Tissue Diseases

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorBastiaan Driehuys

About this trial

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).

Eligibility criteria

Qualifiers

Age: 18-75 years

WHO functional class 2 or 3

Mean pulmonary artery pressures > 20 mmHg

Pulmonary capillary wedge pressure ≤15 mmHg

Disqualifiers

PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.

Trial design

Treatments tested in this trial

129Xe Hyperpolarized

Treatment groups

20 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Bastiaan Driehuys

Lead sponsor

Duke University

Sponsor institution

American Heart Association

Collaborator

Source ClinicalTrials.gov